From Wikipedia, the free encyclopedia
Jump to: navigation, search
Masimo Corporation
Industry Medical Technology
Medical Devices
Medical Monitors
Founders Joe E. Kiani
Headquarters Irvine, California, United States
Area served Worldwide
Revenue US $547.2 million [1]
Employees 3,500 (2014)

Masimo Corporation is an Irvine, California-based manufacturer of non-invasive patient monitoring technologies.[2] The company is best known for its pulse oximetry and it sells more pulse oximeters than any other company.[3] Masimo was founded in 1989 by electrical engineer Joe Kiani, who was later joined by fellow engineer Mohamed Diab.[4] Masimo invented measure-through motion and low perfusion pulse oximetry, known as Masimo SET (Signal Extraction Technology). Masimo has been recognized for its intellectual property and for being one of the most innovative companies in the medical device industry.[5] The company went public in 2007[6] and is currently traded on the NASDAQ stock exchange under the symbol MASI. In 2011, Forbes named Masimo to its list of top 20 public companies under a billion dollars in revenue, based on earnings growth, sales growth, and return on equity.[7][8]

On May 2, 2014, Masimo announced it will celebrate its Silver 25th Anniversary with major initiatives to improve patient safety, including a Day of Volunteering in the name of eliminating preventable patient deaths, a donation of $2.5 million to the Masimo Foundation for Ethics, Innovation and Competition in Healthcare,[9] and plans to unveil at least one new clinically significant product a month for the remainder of 2014.

On May 6, 2014, Masimo announced that the largest-ever study of newborn screening for congenital heart disease (CHD) was published online by The Lancet.[10] The study of 122,738 newborns – more than twice as large as any previous study of this type – was conducted using Masimo SET® Measure-through Motion and Low Perfusion™ Pulse Oximetry and showed that Masimo SET® pulse oximetry screening significantly increased the rate of CHD detection and is “feasible and reliable” for detecting major congenital heart disease.

Masimo SET pulse oximetry[edit]

Conventional pulse oximetry assumes that arterial blood is the only blood moving (pulsating) in the measurement site. However, during patient motion, the venous blood also moves, which can cause conventional pulse oximetry to under-read arterial oxygen saturation levels because it cannot distinguish between the arterial and venous blood.[11][12] Masimo Signal Extraction Technology (SET) identifies the venous blood signal (which has a lower oxygen saturation level than arterial blood), isolates it, and uses adaptive filters to cancel the noise and extract the arterial signal in order to report accurate arterial oxygen saturation and pulse rate. Multiple studies have shown that Masimo SET increases pulse oximetry's ability to detect life-threatening events and reduce false alarms.[13][14] Additional studies have also shown the impact of Masimo SET on patient outcomes, such as helping clinicians detect congenital heart disease in newborns and reduce retinopathy of prematurity in premature infants.[15][16]

The Masimo Radical-7 is a pulse oximeter that can also non-invasively measure a patient's hemoglobin and respiration rate.
Pronto-7 hand-held device for non-invasive hemoglobin, SpO2, pulse rate, and perfusion index

Rainbow pulse CO-Oximetry[edit]

Rainbow pulse CO-Oximetery continuously and non-invasively measures hemoglobin (SpHb), carboxyhemoglobin (SpCO), methemoglobin (SpMet), and pleth variability index (PVI), in addition to oxyhemoglobin (SpO2), perfusion index (PI) and pulse rate.[17] A study at Massachusetts General Hospital showed that SpHb monitoring helped clinicians decrease the frequency of patients receiving blood transfusions during surgery from 4.5% to 0.6%.[18] Emergency department studies have shown that SpCO increases the detection of carbon monoxide poisoning and decreases the time to treatment compared to invasive methods.[19][20] Another study showed that PVI monitoring helped clinicians decrease fluid administered during surgery and reduce patient risk.[21] In 2012, the National Health Service (NHS) Technology Adoption Centre in the United Kingdom advised hospitals to use Intraoperative Fluid Management Technologies as a way to improve patient outcomes, and included Masimo's PVI among technologies available for helping clinicians manage fluid during surgeries.[22]

The Pronto-7 has been recognized with a gold Medical Design Excellence Award.[23] The World Health Organization called non-invasive hemoglobin an “innovative medical technology for cost-effectively addressing global health concerns and needs”.[24]

Patient SafetyNet[edit]

Masimo SafetyNet is a remote monitoring and notification system designed for patients on general care floors.[25] A large study by Dartmouth-Hitchcock Medical Center showed SafetyNet helped clinicians achieve a 65% reduction in distress codes and rescue activations and a 48% decrease in patient transfers to intensive care units, yielding a savings of 135 ICU days annually for an annual opportunity-cost savings of $1.48 million.[26][27] ECRI Institute gave Dartmouth its Health Devices Achievement Award for its use of SafetyNet to prevent "severe patient harm".[28] Masimo recently debuted Halo Index in the SafetyNet system, combining multiple physiologic parameters into one number to help clinicians assess overall patient status.[29]

Rainbow acoustic monitoring[edit]

Rainbow acoustic monitoring provides non-invasive and continuous measurement of respiration rate using an adhesive sensor with an integrated acoustic transducer that is applied to the patient's neck.[30][31] Researchers have evaluated acoustic respiration rate (RRa) and found the acceptable accuracy and significantly fewer false alarms than traditional respiration rate monitoring methods, end-tidal carbon dioxide (EtCO2) and impedance pneumography.[32]

Masimo SET adhesive sensors monitor oxygenation and pulse rate and special rainbow® sensors allow additional measurement of noninvasive blood constituents
True and false SpO2 alarm rate of Masimo SET versus 19 competing pulse oximetry technologies[14]

SedLine anesthetic and sedation monitoring[edit]

In 2010, Masimo acquired SedLine and began offering brain function monitoring to measure the effects of anesthesia and sedation by monitoring both sides of the brain's electrical activity (EEG). Studies have shown this results in more individualized titration and improved care.[33]

Phasein capnography and gas monitoring[edit]

In 2012, Masimo acquired Phasein and began offering ultra-compact mainstream and sidestream capnography as well as multigas analyzers for CO2, N2O, O2, and anesthetic agents, for use in the operating room, procedural sedation, and in intensive care units.[34]

iSpO2 Pulse Oximeter for iPhone, iPad & iPod touch[edit]

iSpO2 is the first commercially available pulse oximeter for iPhone, iPad & iPod touch.[35] Available on Amazon, iSpO2 uses the same standard-of-care pulse oximetry technology found in Masimo’s line of pulse oximeters and Pulse CO-Oximeters used in hospitals around the world.

Clinton Global Initiative[edit]

In 2012, Masimo embarked on its first Commitment to Action with the Clinton Global Initiative (CGI) to solve the global problem of maternal mortality and anemia. The $1 million, two-year project initially focuses on five villages in Liberia and Uganda – two countries where the epidemics of maternal mortality and anemia are among the worst.[36]

FDA clearance for CCHD screening[edit]

In 2012, Masimo received U.S. FDA 510(k) clearance for Masimo Signal Extraction Technology® (SET®) pulse oximeters, rainbow® SET® Pulse CO-Oximeters®, and neonatal sensors with labeling for screening newborns for critical congenital heart disease (CCHD). It marked the first time the FDA cleared specific labeling indicating the use of pulse oximeters, in conjunction with a physical exam, to screen newborns for CCHD.[37]

Masimo CEO Joe Kiani named entrepreneur of the year[edit]

In 2012, Joe Kiani, founder, CEO and Chairman of the Board of Masimo Corporation was named the Ernst & Young National Entrepreneur of the Year - 2012 Life Sciences Award Winner. Kiani was recognized for "revolutionizing the health care industry by taking risks to create and commercialize noninvasive patient monitoring devices, which include an array of sensors that lead to improved accuracy, a reduction in the overall number of false readings, and ultimately, reduced cost of care."[38]

Masimo announces Root[edit]

On June 3, 2013, Masimo announced CE Mark and international Limited Market Release of Root™, an intuitive patient monitoring and connectivity platform designed to transform patient care from the operating room to the general floor.

Root™ in trend view mode.


  1. ^ "U.S. Securities and Exchange Commission | Homepage". Retrieved 2013-05-20. 
  2. ^ "Masimo Corporation: NASDAQ:MASI quotes & news - Google Finance". Retrieved 2012-08-05. 
  3. ^ "iData Research, Inc. Research Reports". Retrieved 2012-08-05. 
  4. ^
  5. ^ "Masimo Recognized As Top 10 Innovator In Medical Device Industry". Retrieved 2012-08-05. 
  6. ^ "Masimo Corporation [MASI] - 08/07/2008". 2008-08-07. Retrieved 2012-08-05. 
  7. ^ Badenhausen, Kurt (19 October 2011). Forbes |url= missing title (help). 
  8. ^ Badenhausen, Kurt. Forbes |url= missing title (help). 
  9. ^ "Masimo Celebrates 25th Anniversary of its Incorporation with Major Initiatives to Improve Patient Safety". Marketwired. 2014-05-02. 
  10. ^ Zhao Q-m, Ma X-j, Ge X-l, Liu F, Yan W-l, Wu L, Ye M, Liang X-c, Zhang J, Gao Y, Jia B, Huang G-y (2014-04-23). "Neonatal Congenital Heart Disease screening group. Pulse oximetry with clinical assessment to screen for congenital heart disease in neonates in China: a prospective study.". The Lancet. Early Online Publication. doi:10.1016/S0140-6736(14)60198-7. 
  11. ^ Mardirossian, George; Schneider, Ronald E. (1992). "Limitations of pulse oximetry". Anesthesia Progress 39 (6): 194–6. PMC 2148612. PMID 8250340. 
  12. ^ Barker, SJ; Tremper, KK (1987). "Pulse oximetry: Applications and limitations". International anesthesiology clinics 25 (3): 155–75. doi:10.1097/00004311-198702530-00010. PMID 3323062. 
  13. ^ Malviya, S; Reynolds, PI; Voepel-Lewis, T; Siewert, M; Watson, D; Tait, AR; Tremper, K (2000). "False alarms and sensitivity of conventional pulse oximetry versus the Masimo SET technology in the pediatric postanesthesia care unit". Anesthesia and Analgesia 90 (6): 1336–40. doi:10.1097/00000539-200006000-00013. PMID 10825316. 
  14. ^ a b USA (2012-05-24). ""Motion-resistant" pulse oximetry: a comparison... [Anesth Analg. 2002] - PubMed - NCBI". Retrieved 2012-08-05. 
  15. ^ De-Wahl Granelli, A.; Wennergren, M.; Sandberg, K.; Mellander, M.; Bejlum, C.; Inganas, L.; Eriksson, M.; Segerdahl, N.; Agren, A.; Ekman-Joelsson, B.-M.; Sunnegardh, J.; Verdicchio, M.; Ostman-Smith, I. (2009). "Impact of pulse oximetry screening on the detection of duct dependent congenital heart disease: A Swedish prospective screening study in 39 821 newborns". BMJ 338: a3037–a3037. doi:10.1136/bmj.a3037. 
  16. ^ Castillo, Armando; Deulofeut, Richard; Critz, Ann; Sola, Augusto (2011). "Prevention of retinopathy of prematurity in preterm infants through changes in clinical practice and SpO2 technology". Acta Paediatrica 100 (2): 188–192. doi:10.1111/j.1651-2227.2010.02001.x. PMC 3040295. PMID 20825604. 
  17. ^ "Masimo Rainbow SET Pulse CO-Oximetry Technology Shown Effective And Efficient In Detecting Carbon Monoxide Poisoning In Multiple Clinical Settings". Retrieved 2012-08-05. 
  18. ^ "Anesthesiology News". Anesthesiology News. Retrieved 2012-08-05. 
  19. ^ Suner, S; Partridge, R; Sucov, A; Valente, J; Chee, K; Hughes, A; Jay, G (2008). "Non-invasive pulse CO-oximetry screening in the emergency department identifies occult carbon monoxide toxicity". The Journal of emergency medicine 34 (4): 441–50. doi:10.1016/j.jemermed.2007.12.004. PMID 18226877. 
  20. ^ Hampson N. Noninvasive pulse CO-oximetry expedites evaluation and management of patients with carbon monoxide poisoning. Am J Emerg Med. 2012 May 23.
  21. ^ Forget, Patrice; Lois, Fernande; De Kock, Marc (2010). "Goal-Directed Fluid Management Based on the Pulse Oximeter–Derived Pleth Variability Index Reduces Lactate Levels and Improves Fluid Management". Anesthesia & Analgesia: 1. doi:10.1213/ANE.0b013e3181eb624f. 
  22. ^ "IOFM Technology Adoption Pack Published". Retrieved 2012-08-05. 
  23. ^ "Award Winners | Medical Design Excellence Awards". 2005-10-22. Retrieved 2012-08-05. 
  24. ^  Missing or empty |title= (help)
  25. ^ Gene Ostrovsky (2007-10-17). "Masimo Patient SafetyNet". Retrieved 2012-08-05. 
  26. ^ "Geisel School of Medicine - Closer watch, fewer ICU trips, Dartmouth anesthesiologists find". 2010-03-05. Retrieved 2012-08-05. 
  27. ^ "APSF Newsletter Spring-Summer 2012". Retrieved 2012-08-05. 
  28. ^ "ECRI Institute Announces Winner of 4th Annual Health Devices Achievement Award". Retrieved 2012-08-05. 
  29. ^ Gene Ostrovsky (2010-10-14). "Masimo to Release New Halo Index, Radical 7 Pulse Oximeter, Patient SafetyNet Monitoring System". Retrieved 2012-08-05. 
  30. ^ "FDA Clears Masimo Rainbow SET Acoustic Respiration Rate Monitor | News | RT: For Decision Makers in Respiratory Care". Retrieved 2012-08-05. 
  31. ^ "Abstract". ASA Abstracts. 2010-10-18. Retrieved 2012-08-05. 
  32. ^ Goudra B., Penugonda L. "Monitoring Respiration in Upper GI Endoscopy Anesthesia" ASA 2011 Presentation A246.
  33. ^ "Patient State Index: Titration of Delivery and Recovery from... : Anesthesiology". Retrieved 2012-08-05. 
  34. ^ "Masimo Enters Noninvasive Multigas Monitoring, including Capnography, with Acquisition of PHASEIN". 2012-08-01. Retrieved 2012-08-05. 
  35. ^ "Masimo iSpO2 Pulse Oximeter for iPhone, iPad & iPod touch". Amazon. 2012-12-12. Retrieved 2012-12-12. 
  36. ^ "Masimo Announces $1 Million Commitment to Action with the Clinton Global Initiative to Solve Maternal Mortality & Anemia". 2012-09-25. Retrieved 2012-09-25. 
  37. ^ "Masimo Oximeters and Neonatal Sensors Receive FDA 510(k) Clearance with Labeling for Use in Newborn Screening for Critical Congenital Heart Disease (CCHD)". 2012-09-26. Retrieved 2012-09-26. 
  38. ^ "Creator of Non-Invasive Patient Monitoring Devices: Masimo Corporation Founder and CEO Joe Kiani Named Ernst & Young National Entrepreneur Of The Year® 2012 Life Sciences Award Winner". 2012-11-18. 

External links[edit]